

## Panitumumab PRIME

## PRELIMINARY SCORE

## CURATIVE



## NON-CURATIVE



## ADJUSTMENTS

## Quality of life



## Serious and disabling adverse effects



## Other adjustments



## Panitumumab PRIME

## FINAL SCORE

## CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

## NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

## INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: First-line treatment of patients with wild-type RAS mCRC

Experimental Arm: Panitumumab + FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)

Control Arm: FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)

